Karyopharm Therapeutics Inc. has announced the granting of 666 restricted stock units (RSUs) to two newly-hired employees as of June 30, 2025. These RSUs were awarded under the company's 2022 Inducement Stock Incentive Plan, in line with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over three years, with one-third vesting on each anniversary of the grant date, contingent upon the employees' continued service. Additionally, the RSUs will become fully exercisable if the employee's employment is terminated for "good reason" or without "cause" within a year of a "change in control event."
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.